Table 3.
Univariable and multivariable analyses (COX regression) identifying independent risk factors for OS of patients with MDS with thrombocytopenia
| Variable | OS | ||||
|---|---|---|---|---|---|
| Univariate Cox | Multivariate Cox | ||||
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age (≧60 y vs <60 y)* | 2.708 (2.066-3.551) | .000 | 1.458 (0.960-2.214) | .077 | |
| Sex (male vs female) | 1.575 (1.190-2.085) | .001 | 1.297 (0.863-1.951) | .211 | |
| IPSS-R (higher risk vs lower risk) | 2.940 (2.142-4.035) | .000 | 2.867 (1.715-4.793) | .000 | |
| Group (C&B vs A) | 1.957 (1.280-2.992) | .002 | 1.846 (1.003-3.398) | .049 | |
| WT1 (≥4.9% vs <4.9%) | 1.782 (1.348-2.357) | .000 | 1.522 (1.011-2.292) | .044 | |
| PRAME (≥0.3% vs <0.3%) | 3.104 (1.852-5.203) | .000 | 1.855 (1.040-3.308) | .036 | |
| Treatment (HSCT vs chemotherapy and HMA) | 0.505 (0.346-0.735) | .000 | 0.355 (0.193-0.653) | .001 | |
| Variable | OS | ||||
|---|---|---|---|---|---|
| Univariate Cox | Multivariate Cox | ||||
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age (≧60 y vs <60 y)* | 2.708 (2.066-3.551) | .000 | 1.458 (0.960-2.214) | .077 | |
| Sex (male vs female) | 1.575 (1.190-2.085) | .001 | 1.297 (0.863-1.951) | .211 | |
| IPSS-R (higher risk vs lower risk) | 2.940 (2.142-4.035) | .000 | 2.867 (1.715-4.793) | .000 | |
| Group (C&B vs A) | 1.957 (1.280-2.992) | .002 | 1.846 (1.003-3.398) | .049 | |
| WT1 (≥4.9% vs <4.9%) | 1.782 (1.348-2.357) | .000 | 1.522 (1.011-2.292) | .044 | |
| PRAME (≥0.3% vs <0.3%) | 3.104 (1.852-5.203) | .000 | 1.855 (1.040-3.308) | .036 | |
| Treatment (HSCT vs chemotherapy and HMA) | 0.505 (0.346-0.735) | .000 | 0.355 (0.193-0.653) | .001 | |
Group A, isolated thrombocytopenia group; Group B, bicytopenia group; Group C, pancytopenia group; HSCT, hematopoietic stem cell transplantation; OS, overall survival; PFS, progression-free survival PRAME, preferentially expressed antigen of melanoma; WT1, Wilms tumor 1.
*
Age was included in the analysis as a categorical variable on the basis of a best-split algorithm showing a statistical difference in OS between patients younger than 60 years and those aged 60 years or older (supplemental Figure 5A-B,D-E).